1. Scrip
  2. >>Business

AC Immune Keeps Faith In Alzheimer’s Breakthrough, But Spreads Risk With Parkinson’s Bet

Broadened Pipeline And Prevention Strategy

 
• By Andrew McConaghie

Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.

Alzheimer's PET scan
AC Immune is aiming to intercept Alzheimer's years before symptoms start to appear, by which time damaged caused by beta amyloid and tau is currently irreversible.

AC Immune has suffered major disappointments in its efforts to develop an Alzheimer’s therapy in its near-20 year history, but it is hoping a switch to preventing rather that treating dementia, and a multi-pronged strategy across neurodegenerative disease, could help it finally achieve success.

Chief executive and co-founder Andrea Pfeifer has managed to keep the Switzerland-based company moving forward despite its development setbacks, and in June announced the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip